There have been 23 PR’s regarding Brilacidin for CV19 since the initial PR on 2/18/20. Each of these PR’s positively and progressively build towards the success for B-CV19 as a premier treatment for a pandemic that is in dire need of effective therapeutics. Today we learned that Brilacidin is not only effective in inhibiting CV19 from infecting healthy cells but it has now been confirmed that Brilacidin is an effective treatment for cells that have previously been infected by the virus.
“As Brilacidin is showing consistent and robust anti-SARS-CoV-2 activity across the viral lifecycle, the Company believes the drug could be used as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected.”
As Ultimate mentioned there is a huge demand for an effective prophylactic treatment for critical workers including heath care workers, EMT’s and military personnel. Human life and safety are the obvious priority for an effective CV19 treatment.
There are also economic considerations that are much less important than the above mentioned but have a huge demand for the safety of non-critical workers. One example of this would be for professional sports teams. There are hundreds of millions of dollars at stake for professional sports teams that are struggling to stay viable as player safety is extremely difficult to ensure and maintain. Using Brilacidin as an effective prophylactic treatment would provide player safety and could save entire industries.
Today’s announcement solidifies that Brilacidin consistently works throughout the virus life cycle. IMO if the upcoming B-CV19 human trials mirror the proven lab results, Brilacidin will be the top CV19 treatment for both pre and post infection. This is extremely exciting news and confirmation of how valuable the Brilacidin asset is to IPIX shareholders. President Trump has mentioned the ideal of a CV19 patient going to a hospital and getting a treatment that basically cures CV19 and today’s announcement brings us closer to that vision becoming a reality.
I also believe today’s filed Aspire agreement is a very smart move by Leo. This agreement allows IPIX to advance Brilacidin on multiple fronts (B-CV19, B-IBD Oral, B-OM) INDEPENDENT of government grant funding and/or BP partnerships. This agreement is basically a $30M line of credit that can be accessed at Leo’s discretion. I strongly believe that IPIX will indeed get grant funding for CV19 and that there will be partnerships in the future for other Brilacidin instances. The Aspire agreement gives Leo the ability to proceed with science advancements on multiple fronts on his own timeline without the DEPENDENCY on outside funding. This puts IPIX in a much stronger position financially and strategically.
Today’s outstanding PR is also a proof point that IPIX SP continues to be criminally controlled by a Non Retail (NR) entity. Only in this heavily manipulated and upside down environment would on-going outstanding news of a Gold Star CV19 treatment for a deadly pandemic be met with a couple penny decrease in SP. This criminal control will continue in the short term but will soon lose its grip as IPIX continues to advance the science and reach significant milestones of peer reviews, grant funding and most importantly successful human CV19 trials and a successful IND for Brilacidin.
“As Brilacidin is showing consistent and robust anti-SARS-CoV-2 activity across the viral lifecycle, the Company believes the drug could be used as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected.”
As Ultimate mentioned there is a huge demand for an effective prophylactic treatment for critical workers including heath care workers, EMT’s and military personnel. Human life and safety are the obvious priority for an effective CV19 treatment.
There are also economic considerations that are much less important than the above mentioned but have a huge demand for the safety of non-critical workers. One example of this would be for professional sports teams. There are hundreds of millions of dollars at stake for professional sports teams that are struggling to stay viable as player safety is extremely difficult to ensure and maintain. Using Brilacidin as an effective prophylactic treatment would provide player safety and could save entire industries.
Today’s announcement solidifies that Brilacidin consistently works throughout the virus life cycle. IMO if the upcoming B-CV19 human trials mirror the proven lab results, Brilacidin will be the top CV19 treatment for both pre and post infection. This is extremely exciting news and confirmation of how valuable the Brilacidin asset is to IPIX shareholders. President Trump has mentioned the ideal of a CV19 patient going to a hospital and getting a treatment that basically cures CV19 and today’s announcement brings us closer to that vision becoming a reality.
I also believe today’s filed Aspire agreement is a very smart move by Leo. This agreement allows IPIX to advance Brilacidin on multiple fronts (B-CV19, B-IBD Oral, B-OM) INDEPENDENT of government grant funding and/or BP partnerships. This agreement is basically a $30M line of credit that can be accessed at Leo’s discretion. I strongly believe that IPIX will indeed get grant funding for CV19 and that there will be partnerships in the future for other Brilacidin instances. The Aspire agreement gives Leo the ability to proceed with science advancements on multiple fronts on his own timeline without the DEPENDENCY on outside funding. This puts IPIX in a much stronger position financially and strategically.
Today’s outstanding PR is also a proof point that IPIX SP continues to be criminally controlled by a Non Retail (NR) entity. Only in this heavily manipulated and upside down environment would on-going outstanding news of a Gold Star CV19 treatment for a deadly pandemic be met with a couple penny decrease in SP. This criminal control will continue in the short term but will soon lose its grip as IPIX continues to advance the science and reach significant milestones of peer reviews, grant funding and most importantly successful human CV19 trials and a successful IND for Brilacidin.
15
